Elite Pharma FY2024 revenue $56.6M (+65% YoY); operating profit $10.8M (+192%)

ELITE PHARMACEUTICALS INC /NV/

2025-Q1 EPS reported $0.00 revenue$18,803,063

Revenue of $56.6M, up $22.4M (65%) from prior fiscal year.
Operating profit $10.8M, up $7.1M (192%) YoY.
Net income attributable to common shareholders was $20.1M.
Growth driven by commercial launch of Elite label product line in FY2024.
Conference call on July 2, 2024 at 11:30 AM EDT for business update.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.